Abstract:Background: Metabolic reprogramming is a characteristic of tumor cells and is considered a potential therapeutic target. Even under aerobic conditions, tumor cells use glycolysis to produce energy, a phenomenon called the "Warburg effect". Pyruvate dehydrogenase kinase 1 (PDK1) is a key factor linking glycolysis and the tricarboxylic acid cycle. Dichloroacetic acid (DCA) reverses the Warburg effect by inhibition of PDKI to switch cytoplasmic glucose metabolism to mitochondrial oxidative phosphorylation (OXPHOS).Methods: Cell viability was examined using a standard MTT assay. Glucose consumption and L-lactate production were measured using commercial colorimetric kits, and intracellular lactate dehydrogenase (LDH) activity was evaluated using cell lysates and an LDH Quantification Kit. Real-time PC R was used to detect the expression of related genes. The production of total ROS was evaluated by staining with dichlorofluorescin diacetate.Results: Comparison of various aspects of glucose metabolism, such as expression of key enzymes in glycolysis, lactate production, glucose consumption, mitochondrial oxygen consumption rate, and citric acid production, revealed that A2780/DDP cells were primarily dependent on glycolysis whereas A2780 cells were primarily dependent on mitochondrial OXPHOS. Mitochondrial uncoupling protein 2 (UCP2) protects against mitochondrial ROS while allowing energy metabolism to switch to glycolysis. Treatment of A2780 cells with various concentrations of DCA resulted in decreased expression of UCP2, a metabolic switch from glycolysis to mitochondrial OXPHOS, and an increase in oxidative stress induced by ROS. These effects were not observed in A2780/DDP cells with higher UCP2 expression suggesting that UCP2 might induce changes in mitochondrial functions that result in different sensitivities to DCA.Conclusion: Our results show that a drug targeting tumor metabolic changes affects almost the entire process of glucose metabolism. Thus, it is necessary to comprehensively determine tumor metabolic functions to facilitate individualized antitumor therapy.

Dichloroacetate enhances adriamycin-induced hepatoma cell toxicity in vitro and in vivo by increasing reactive oxygen species levels

Curcumin enhanced adriamycin-induced human liver-derived Hepatoma G2 cell death through activation of mitochondria-mediated apoptosis and autophagy.

Dichloroacetate Enhances the Antitumor Efficacy of Chemotherapeutic Agents Via Inhibiting Autophagy in Non-Small-cell Lung Cancer

Diethyldithiocarbamate May Enhance the Antitumor Effect of Adriamycin Nanoparticle-Lipiodol Emulsion

Dichloroacetic Acid Upregulates Apoptosis Of Ovarian Cancer Cells By Regulating Mitochondrial Function

Dichloroacetate shifts the metabolism from glycolysis to glucose oxidation and exhibits synergistic growth inhibition with cisplatin in HeLa cells.

Impact of Sodium Dichloroacetate Alone and in Combination Therapies on Lung Tumor Growth and Metastasis

DCA Increases the Antitumor Effects of Capecitabine in a Mouse B16 Melanoma Allograft and a Human Non-Small Cell Lung Cancer A549 Xenograft.

Effects of Dichloroacetate on the Activation of the Mitochondrial Pathway in C6 Cells in Vitro

Superior anti-tumor efficacy of diisopropylamine dichloroacetate compared with dichloroacetate in a subcutaneous transplantation breast tumor model.

Enhanceing Antitumor Effect of Adriamycin Nanoparticle - Lipiodol Emulsion by Pretreating Tumor Cells with Diethyldithiocarbamate

Targeted Cancer Therapy with A 2-Deoxyglucose-based Adriamycin Complex

Dauricine upregulates the chemosensitivity of hepatocellular carcinoma cells: Role of repressing glycolysis via miR-199a:HK2/PKM2 modulation.

Antitumor Activity of Dichloroacetate on C6 Glioma Cell: in Vitro and in Vivo Evaluation

Synergistic Antitumor Effect of Dichloroacetate in Combination with 5-Fluorouracil in Colorectal Cancer

Inhibition of autophagy promotes apoptosis and enhances anticancer efficacy of adriamycin via augmented ROS generation in prostate cancer cells

Dichloroacetate and PX-478 exhibit strong synergistic effects in a various number of cancer cell lines

The Glutaminase-1 Inhibitor 968 Enhances Dihydroartemisinin-Mediated Antitumor Efficacy In Hepatocellular Carcinoma Cells

Synergy and Attenuation Effects of Dihydromyricetin on Tumor-Bearing Mice Affected by Breast Cancer Treated with Chemotherapy

Dichloroacetate restores colorectal cancer chemosensitivity through the p53/miR-149-3p/PDK2-mediated glucose metabolic pathway

Metabolism targeting therapy of dichloroacetate-loaded electrospun mats on colorectal cancer